Yama F Mujadidi
BCA Computer Application , MSc in Information Technology and Software Engineering
Clinical Trials IT and Development Lead
Yama F Mujadidi has expertise in the design and development of software and is currently working with Oxford Vaccine Group in the capacity of Clinical Trials IT and Development Lead. He acquired an MSc in Information Technology from University of Bradford United Kingdom, in 2012 after he earned a First class degree in BCA Computer Application from the University of Pune, in the year 2010.
Yama joined Oxford Vaccine Group in June 2013 and tasked to provide specialist advice to research groups to improve quality of clinical trials and to develop an application based on the vaccine knowledge project for use in smart-phones/tablets. Before Oxford Vaccine Group, He had been working with Omni Communication Product Limited as a software developer and contributed to the development of a multi-communication application for use in smartphones and tablets.
Recent publications
-
Journal article
Liu X. et al, (2022), J Infect
-
Journal article
Ogbe A. et al, (2022), JCI Insight
-
Journal article
Stuart ASV. et al, (2021), Lancet
-
Journal article
Munro APS. et al, (2021), Lancet
-
Journal article
Clemens SAC. et al, (2021), Nature Communications, 12
-
Journal article
Shakya M. et al, (2021), Lancet Glob Health, 9, e1561 - e1568
-
Journal article
Theiss-Nyland K. et al, (2021), Clin Infect Dis
-
Journal article
Clemens SAC. et al, (2021), Nat Commun, 12
-
Journal article
Swanson PA. et al, (2021), Science translational medicine, eabj7211 - eabj7211
-
Journal article
Feng S. et al, (2021), Nat Med
-
Journal article
Liu X. et al, (2021), Lancet, 398, 856 - 869
-
Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002)
Journal article
EWER K. et al, (2021), The Lancet
-
Journal article
Qadri F. et al, (2021), Lancet, 398, 675 - 684
-
Journal article
Swanson PA. et al, (2021), medRxiv
-
Journal article
Liu X. et al, (2021), SSRN Electronic Journal
-
Journal article
Flaxman A. et al, (2021), SSRN Electronic Journal
-
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm sub-study of a phase 2/3 clinical trial
Journal article
EWER K. et al, (2021), Lancet HIV
-
Journal article
Shaw RH. et al, (2021), Lancet, 397, 2043 - 2046
-
Journal article
Barrett JR. et al, (2021), Nature medicine
-
Journal article
Barrett JR. et al, (2021), Nature medicine
-
Frater J. et al, (2021)
-
Journal article
Emary KRW. et al, (2021), Lancet, 397, 1351 - 1362
-
Journal article
Madhi SA. et al, (2021), New England Journal of Medicine, 384, 1885 - 1898
-
Journal article
Voysey M. et al, (2021), Lancet, 397, 881 - 891
-
Journal article
Bendor-Samuel OM. et al, (2021)
-
Journal article
Emary KRW. et al, (2021), SSRN Electronic Journal
-
Journal article
Voysey M. et al, (2021), The Lancet
-
Journal article
Ramasamy MN. et al, (2021), Lancet, 396, 1979 - 1993
-
Journal article
Thindwa D. et al, (2020), Wellcome Open Research, 5, 66 - 66
-
T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a Phase 1/2 clinical trial.
Journal article
LAMBE T. et al, (2020), Nature Medicine